Immunoprecise Historical Valuation

IPA -  USA Stock  

USD 4.14  0.15  3.50%

Some fundamental drivers such as market cap or Immunoprecise Antibodies enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Immunoprecise Antibodies valuation indicators such as Enterprise Value of 138.9 M or Invested Capital of 8 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Immunoprecise Antibodies's future value. Financial Statement Analysis is much more than just reviewing and breaking down Immunoprecise Antibodies prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunoprecise Antibodies is a good buy for the upcoming year.
Please see Risk vs Return Analysis.
  
Refresh
Share

About Immunoprecise Valuation Data Analysis

Valuation is the financial process of determining what Immunoprecise Antibodies is worth. Immunoprecise Antibodies valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Immunoprecise Antibodies valuation ratios help investors to determine whether Immunoprecise Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunoprecise with respect to the benefits of owning Immunoprecise Antibodies security.

Immunoprecise Antibodies Valuation Data Chart

Immunoprecise valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Immunoprecise equity instrument and the benefits of owning shares of Immunoprecise Antibodies.
Immunoprecise Antibodies Tangible Asset Value is projected to increase significantly based on the last few years of reporting. The past year's Tangible Asset Value was at 61.09 Million. The current year Working Capital is expected to grow to about 53.1 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (1.8 M).

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from Total Assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Immunoprecise Antibodies theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Immunoprecise Antibodies debt, but would also pocket its cash. Enterprise Value is more accurate representation of Immunoprecise Antibodies value than its market capitalization because it takes into account all of Immunoprecise Antibodies existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

Market Capitalization

Market capitalization (or market cap) is the total value of the shares outstanding of Immunoprecise Antibodies. It is equal to Immunoprecise Antibodies current share price times the number of Immunoprecise Antibodies outstanding shares. Represents the product of [SharesBas]; [Price] and [ShareFactor].
Most indicators from Immunoprecise Antibodies valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Immunoprecise Antibodies Tangible Asset Value is projected to increase significantly based on the last few years of reporting. The past year's Tangible Asset Value was at 61.09 Million. The current year Working Capital is expected to grow to about 53.1 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (1.8 M).
 2010 2021 2022 (projected)
Enterprise Value155.2 M139.68 M138.86 M
Average Equity16.58 M40.3 M36.15 M

Immunoprecise Antibodies valuation accounts Correlations

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies Investors Sentiment

The influence of Immunoprecise Antibodies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunoprecise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immunoprecise Antibodies Implied Volatility

    
  304.15  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Current Sentiment - IPA

Immunoprecise Antibodies Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunoprecise Antibodies. What is your judgment towards investing in Immunoprecise Antibodies? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
101.5 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.